Figure 1. Decreased LINC00968 is related to the patient's pathological grade and prognosis in LUAD. (A) Identification of common significantly differentially expressed lncRNAs from four independent LUAD microarray analyses using the GEO2R analysis online tools. (B) The levels of LINC00968 expression were downregulated in tumor tissues compared with that of non-tumor lung tissues (GSE19188, GSE27262, GSE40791, and GSE30219). (C) LINC00968 expression in LAC and non-tumor tissues based on the data from the GSE18842 and TANRIC databases. (D) The levels of LINC00968 expression were validated by in situ hybridization histochemistry in tissue biopsies. (E) The area under the curve (AUC) of LINC00968 levels in LAC patients based on a microarray, ranged from 0.9501 to 1.000, proving that LINC00968 was an effective diagnostic molecular marker for LAC patients. (F) Low LINC00968 expression was associated with advanced disease stages in the GSE50081 and GSE30219 datasets (clinical stages, N stages, and T stages). (G) Based on the TANRIC database, the relationship between LINC00968 expression and advanced disease stages was further validated (clinical stages, N stages, and T stages). (H) Kaplan-Meier overall survival curves and Kaplan-Meier estimates of time to the first progression for patients with LAC classified according to relative LINC00968 expression level. (I) Low expression of LINC00968 was associated with shorter overall survival and disease-free survival time.